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ABSTRACT
Background. Although rapidly progressive glomerulonephritis is the main renal phenotype of anti-neutrophil cytoplasmic
antibody (ANCA)-associated vasculitis (AAV), slow renal disease progression is sometimes observed. These forms have been
rarely discussed; we analysed their prevalence, clinico-pathological characteristics and outcome.
Methods. We screened patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis followed at seven
referral centres and selected those with estimated glomerular filtration rate (eGFR) reduction <50% over a 6-month period
preceding diagnosis. Data regarding patient features and response to treatment were retrieved.
Received: 20.1.2020; Editorial decision: 25.5.2020
VC The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
For commercial re-use, please contact journals.permissions@oup.com
332
Clinical Kidney Journal, 2021, vol. 14, no. 1, 332–340
doi: 10.1093/ckj/sfaa139
Advance Access Publication Date: 6 September 2020
Original Article
Results. Of 856 patients, 41 (5%) had slowly progressive renal AAV. All had MPA and all but one was P-ANCA/
myeloperoxidase (MPO) ANCA-positive. At diagnosis, the median age was 70 years [interquartile range (IQR) 64–78] and
extra-renal manifestations were absent or subclinical (interstitial lung lesions in 10, 24%). The median (IQR) eGFR was
23 mL/min/1.73 m2 (15–35); six patients (15%) had started renal replacement therapy (RRT). All had proteinuria (median
1180 mg/24 h, IQR 670–2600) and micro-haematuria. Main histologic findings were extracapillary proliferation at chronic
stages and glomerulosclerosis; following Berden’s classification, 6/28 biopsies (21%) were ‘focal’, 1/28 (4%) ‘crescentic’, 9/28
(32%) ‘mixed’ and 12/28 (43%) ‘sclerotic’. At last follow-up (median 32 months, IQR 12–52), 20/34 patients (59%) treated with
immunosuppression had eGFR improvement >25% as compared with diagnosis, while 4/34 (12%) had started RRT.
Conclusions. AAV may present with slow renal disease progression; this subset is hallmarked by advanced age at diagnosis,
positive MPO-ANCA, subclinical interstitial lung lesions and chronic damage at kidney biopsy. Partial renal recovery may
occur following immunosuppression.
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INTRODUCTION
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vascu-
litis (AAV) is a necrotizing vasculitis characterized by small-
vessel inflammation and circulating autoantibodies directed
against proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-
ANCA) [1]. Renal involvement is a major complication of the
two main AAV variants, granulomatosis with polyangiits (GPA)
and microscopic polyangiitis (MPA) [2, 3], and usually manifests
with rapidly progressive glomerulonephritis (RPGN) [4]. This re-
nal syndrome is hallmarked by a rapid decline in glomerular fil-
tration rate (GFR), an active urinary sediment for the presence
of erythrocyte casts and histological findings of pauci-immune
necrotizing crescentic glomerulonephritis [5]. RPGN requires an
early induction treatment with glucocorticoids and immuno-
suppressive drugs, e.g. cyclophosphamide or rituximab, to stop
vasculitis activity and restore renal function [6].
Nevertheless, up to 30% of AAV patients with renal involve-
ment have less aggressive manifestations than RPGN and some
experience an indolent course with slow progression towards
end-stage renal disease (ESRD) [5]. These ‘slowly progressive’ re-
nal AAV forms have been rarely discussed in the literature [7],
with only anecdotal cases reported to date [8–11]. Such peculiar
phenotype probably accounts for a small proportion of AAV, but
its recognition may be challenging, since manifestations are not
typical for vasculitis and also occur in other more prevalent re-
nal diseases. This can result in delayed or missed diagnosis,
with progressive damage accrual. Furthermore, the optimal
management and the outcome of these forms are unknown.
To address these points, we have screened a large multi-
centre cohort of AAV patients, in order to identify cases with
slowly progressive renal course and analyse their prevalence,
clinico-pathological features and outcome. We only considered
patients with MPA and GPA and excluded those with eosino-
philic granulomatosis with polyangiitis, since this AAV syn-
drome has further peculiar manifestations with uncommon
and usually mild renal involvement [12]. Our ultimate goals
were to raise awareness of this possible presentation of AAV
and to explore whether these chronic and apparently irrevers-
ible cases have a chance of recovery.
MATERIALS AND METHODS
Patients
We searched the medical records of AAV patients followed at
seven vasculitis referral centres, namely the Nephrology Units
of Parma University Hospital, Spedali Civili, Brescia, Policlinico
San Matteo, Pavia, San Carlo Borromeo Hospital, Milano, San
Gerardo Hospital, Monza, Italy and the Vasculitis and Lupus
Clinic of the Addenbrooke’s Hospital, Cambridge, UK. We
screened patients classified as GPA or MPA according to the
European Medicines Agency algorithm [13] who had renal in-
volvement at diagnosis, defined as estimated GFR (eGFR)
<90 mL/min/1.73 m2 and urinalysis disclosing proteinuria and/
or haematuria (Supplementary data, Table S1). Patients also had
to be 18 years old at the time of diagnosis and had to have
available ANCA test [indirect immunofluorescence and/or en-
zyme-linked immunosorbent assay (ELISA). AAV cases second-
ary to drugs, cancer, infections or other autoimmune disorders
and patients who had received immunosuppressive therapy
(prednisone >7.5 mg/day or equivalent, or any immunosuppres-
sive agent) during the 6 months before diagnosis were excluded,
in order to avoid any possible influence on renal disease
progression.
We then selected patients with two or more renal function
assessments performed within 6 months before diagnosis and
analysed their GFR deterioration. Slow progression was defined
as eGFR reduction >25% but 50% over the 6-month period pre-
ceding diagnosis. These limits allowed differentiation of slow
renal course from RPGN, usually defined as eGFR reduction
>50% in up to 3 months [5], and from kidney impairment with
no significant progression. The medical history of patients with
slow renal disease progression was reviewed in order to assess
other potential causes of renal dysfunction, e.g. drugs, systemic
illnesses, infections or any established kidney disease. After
consensus was reached among three of the main investigators
(G.T., S.G. and A.V.), we included those whose clinical course
was not significantly influenced by any of these conditions. All
patients signed an informed consent. The study was performed
in accordance with the declaration of Helsinki and received ap-
proval from the Ethics Committee of the University of Firenze,
Italy (protocol number 12097).
Data collection
The time of diagnosis corresponded to the first diagnostic renal
biopsy or, if this was not available, to the occurrence of compat-
ible clinical, laboratory or pathological findings, e.g. ANCA test.
Data regarding demographic and clinical features were re-
trieved from medical records and disease activity was evaluated
using the Birmingham Vasculitis Activity Score (BVAS) version 3
[14]. The patients’ medical history was examined to assess the
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presence of conditions associated with chronic kidney disease
(CKD), i.e. atherosclerotic disease (clinically documented ischae-
mic heart disease, cerebrovascular disease or peripheral artery
disease), diabetes and cardiovascular risk factors. To assess
whether their prevalence was substantially different from that
of the general population, data were compared with results of
Italian and British national surveys (CuoreData, Il Progetto
Cuore, Istituto Superiore di Sanità, www.cuore.iss.it by 29 July
2019; Heart and Circulatory Disease Statistics 2019, British Heart
Foundation).
Renal parameters were collected starting from the first de-
tection of renal disease, i.e. either eGFR <90 mL/min/1.73 m2,
proteinuria (urinary albumin-to-creatinine ratio >30 mg/g or
24 h-proteinuria >150 mg) or glomerular haematuria (>3 cells
per high-power field, red cell casts on urine microscopic exami-
nation or >11 cells/lL on standard urinalysis). eGFR was calcu-
lated using the CKD Epidemiology Collaboration equation [15].
ESRD was defined as eGFR <15 mL/min/1.73 m2 at two consecu-
tive assessments or the need for renal replacement therapy
(RRT). Kidney biopsies were examined by experienced local
pathologists and classified according to the criteria proposed in
2010 by Berden et al. (see Supplementary Methods) [16].
The type of treatment was distinguished into one of the fol-
lowing: (i) no immunosuppressive therapy; (ii) regimens based
on glucocorticoids and conventional immunosuppressive drugs
other than rituximab, e.g. cyclophosphamide; and (iii)
rituximab-based regimens. Outcome data were collected until
last available follow-up, patient death or March 2019, and were
assessed at Months 6, 12 and 24 after diagnosis and at last fol-
low-up.
AAV remission was defined as absence of vasculitis activity
(BVAS¼ 0). ‘Renal response’ was a composite of AAV remission
(BVAS¼ 0) and eGFR improvement (25%) or stabilization as
compared with diagnosis, with concomitant reduction of uri-
nary abnormalities (50% at quantitative measurements).
Those who reported either eGFR worsening (25%) or protein-
uria increase (50% at quantitative measurements) as com-
pared with diagnosis and those who started RRT failed to
achieve response. Relapse was defined as any BVAS modifica-
tion occurring after remission and ‘renal worsening’ as eGFR re-
duction (25%) or any other manifestation occurring after renal
response.
Statistical analysis
Continuous variables, presented as median (interquartile range,
IQR), were compared with the t-test or the Mann–Whitney test,
where appropriate. Categorical variables, presented as n (%),
were compared with the Chi-square test. Median eGFR and 24-h
proteinuria at different time-points were compared using
Friedman’s test. All analyses were performed using Prism ver-
sion 5. P < 0.05 were considered statistically significant.
RESULTS
Patients
A total of 856 patients with primary AAV were screened. The co-
hort included 473 GPA cases (55%) and 383 MPA cases (45%) di-
agnosed between May 1999 and February 2018 (Figure 1). Renal
involvement at diagnosis was reported among 615 patients
(72%), of which 340 (55%) had MPA. Of the 258 patients with
available pre-diagnosis tests, we did not assess the renal course
of 11 who were taking immunosuppressive therapy already
before diagnosis. Among the remaining, RPGN was recognized
or could not be excluded in 173 (70%), while 27 (11%) had non-
progressive kidney dysfunction with minor eGFR fluctuations.
Moreover, six patients (2%) with slow renal disease progression
were not included because this was attributed to other estab-
lished causes, namely obstructive uropathy (1/6), severe cardiac
failure (1/6), drug abuse (2/6) and chronic pyelonephritis (2/6).
We identified 41 patients who met the criteria for slowly pro-
gressive renal AAV. This group accounted for 5% of the screened
cohort and for 17% of patients with pre-diagnosis tests. All had
MPA, corresponding to 11% of the screened MPA cases
(Figure 1).
Demographic and clinical features at diagnosis
At diagnosis, all but one had positive MPO-ANCA or ’perinu-
clear’ pattern at immunofluorescence (P-ANCA) and 30 (73%)
were >65 years (Table 1). Twenty-five patients (61%) had renal-
limited vasculitis, while three (7%) had peripheral neuropathy
confirmed by nerve conduction studies and two (5%) had non-
granulomatous ear–nose–throat manifestations (otitis and se-
rous nasal discharge).
Of the 26 patients with available chest high-resolution com-
puted tomography (HRCT), 10 (38%) had radiological lung abnor-
malities according to the list of MPA-associated lung lesions by
Yamagata et al. (see Supplementary Methods) [17]. The reported
lesions were ground-glass opacities (5/10), interlobular septal
thickening (4/10), honeycombing (3/10), nodular pattern (3/10),
bronchiectasis (2/10) and reticular pattern (1/10). Four (40%)
were current or former smokers, while none had a pre-existing
lung disease, e.g. idiopathic interstitial pneumonia or infection.
A clinico-radiological pattern corresponding to idiopathic pul-
monary fibrosis was recognized in three cases (30%). Moreover,
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FIGURE 1: Study flow diagram. Renal involvement was defined as an eGFR
<90 mL/min/1.73 m2 and urinalysis disclosing proteinuria or haematuria. Pre-
diagnosis data included renal function assessments performed over the 6-
month period preceding diagnosis.
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The prevalence of atherosclerotic disease and risk factors is
shown in Table 1 and appeared similar to that reported by
Italian and British national surveys on population of compara-
ble sex and age.
Renal features and histology
At diagnosis, the median (IQR) eGFR was 23 mL/min/1.73 m2 (15–
35). Fifteen patients (37%) had ESRD and six (15%) required RRT
(Table 2). All had haematuria and proteinuria (for those requir-
ing RRT, we considered last available urinalysis). Five patients
(12%) had urinary protein excretion 3500 mg/24 h but none
showed further features of nephrotic syndrome.
The median (IQR) time elapsed from the first detection of re-
nal abnormalities to diagnosis was 13 months (6–35); this was
significantly longer among patients with ESRD than among
those presenting with eGFR>15 mL/min/1.73 m2, respectively,
38 months (IQR 13–52) and 8 months (IQR 6–16) (P¼ 0.007).
Thirty-eight patients (93%) had three or more renal function
assessments during the pre-diagnosis period. These values
revealed that the eGFR decline had not occurred predominantly
around diagnosis, as in RPGN. Rates of progression slightly var-
ied between patients and between different observation periods
for each patient (data not shown), but were consistent with
gradual worsening. The evolution of eGFR during the 12 months
preceding diagnosis is shown in Supplementary data, Figure S1.
All the 28 patients who underwent kidney biopsy had histol-
ogy consistent with AAV. Extra-capillary proliferation was ob-
served in 25 samples (89%); crescents were purely fibrous in 22
(78%) and cellular or fibro-cellular in three (11%). The median
(IQR) proportion of glomeruli involved by extra-capillary prolif-
eration was 31% (17–53%). Foci of fibrinoid necrosis were found
in five cases (18%), while one (4%) had interstitial vasculitis with
peri-glomerular infiltrates. Furthermore, all biopsies showed
glomerulosclerosis, involving a median (IQR) proportion of 38%
glomeruli (17–67), along with interstitial fibrosis and tubular at-
rophy of varying extent (Figure 2). Eight patients (28%) had se-
vere arteriolar hyalinization. Of the six diabetic patients with
available kidney biopsy, two had glomerular basement mem-
brane thickening by light microscopy but none showed further
diabetic nephropathy lesions. According to the histopathologic
Table 1. Demographic and clinical characteristics of patients with
slowly progressive ANCA-associated renal vasculitis at the time of
diagnosis
n¼ 41
Gender and age, n (%)
Female 21 (51)
Age, median (IQR), years 70 (64–78)
<50 years 5 (12)
50–75 years 20 (49)
>75 years 16 (39)
Type of AAV, n (%)
MPA 41 (100)
GPA 0
ANCA specificity, n (%)
By indirect immunofluorescence
P-ANCA alone 39 (94)
C- and P-ANCA 1 (3)
C-ANCA alone 1 (3)
By ELISA
MPO-ANCA alone 37/39 (94)
MPO- and PR3-ANCA 1/39 (3)
PR3-ANCA alone 1/39 (3)
Clinical manifestations and organ involvement, n (%)
Renal-limited vasculitis 25 (61)
Radiological lung abnormalitiesb 10/26 (38)
Diffuse alveolar haemorrhage 0
Idiopathic pulmonary fibrosis 3/26 (11)
Peripheral nervous system 3 (7)
Ear–nose–throat 2 (5)
Skin 1 (2)
BVAS, median (IQR) 6 (6–10)
Cardiovascular risk factors and comorbidities, n (%)
Arterial hypertension 26 (63)
Diabetes 9 (22)
BMI30 kg/m2 6 (15)
Smoking history (current or former) 13 (32)
Atherosclerotic diseasec 8 (19)
aP-ANCA means ’perinuclear’ pattern, while C-ANCA refers to ’cytoplasmic’
pattern.
bThe presence of radiological lung abnormalities was evaluated in 26 patients
who underwent HRCT of the lungs at diagnosis according to the list of MPA-as-
sociated lung lesions by Yamagata et al. (see Supplementary Methods) [17].
c
Atherosclerotic disease was defined as the presence of at least one of the fol-
lowing documented conditions: coronary artery disease, cerebrovascular dis-
ease, peripheral arterial disease.
BMI, body mass index.
Table 2. Renal characteristics of patients with slowly progressive
ANCA-associated renal vasculitis
n¼ 41
Renal function at diagnosis
Serum creatinine, median (IQR), mg/dL 2.3 (1.8–3.4)
eGFR, median (IQR), mL/min/1.73 m2 23 (15–35)
ESRDa, n (%) 15 (37)
RRT, n (%) 6 (15)
Urinalysis at diagnosisb
Proteinuriac, n (%) 41 (100)
24-h proteinuria, median (IQR), mg/24 h 1180 (670–2600)
3500 mg/24 h, n (%) 5 (12)
Micro-haematuriad, n (%) 41 (100)
Active urinary sedimente, n (%) 2/14 (14)
Renal disease before diagnosis
Time to diagnosis, median (IQR), months 13 (6–35)
Percent loss of eGFR from first assessment, median
(IQR), %
53 (39–73)
Absolute loss of eGFR from first assessment,
median(IQR), mL/min/1.73 m2
25 (17–32)
Slope of eGFR reductionf, median (IQR), mL/min/
1.73 m2/month
1.9 (1.0–3.1)
Renal biopsy category (Berden’s classification) n¼ 28
Focal, n (%) 6 (21)
Crescentic, n (%) 1 (4)
Mixed, n (%) 9 (32)
Sclerotic, n (%) 12 (43)
aESRD was defined as eGFR <15 mL/min/1.73 m2 established at two consecutive
assessments or the need for RRT.
bFor patients in ESRD, we considered the last available follow-up.
cProteinuria was defined as either >150 mg/24 h or albumin/creatinine ratio
>30 mg/g; 24-h proteinuria was available for 33 patients.
dMicro-haematuria was defined as either >3 cells per high-power field or >11
cells/lL on standard urinalysis.
eUrinary sediment was considered active in the presence of red cell casts.
fSlope of eGFR reduction was calculated dividing the absolute loss of eGFR from
first assessment to diagnosis with the number of months elapsed between the
two time points.
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FIGURE 2: Representative renal histology. Renal biopsy specimens of patients with slowly progressive ANCA-associated renal vasculitis: (A) low-power view showing
diffuse glomerular and tubulointerstitial chronic inflammatory and fibrotic lesions, particularly fibrous crescents in all the examined glomeruli. (B) High-power view of
one of the glomeruli seen in (A), showing a circumferential fibrous crescent and a periglomerular, tubulointerstitial mononuclear cell infiltrate. (C) Low-power view im-
age disclosing chronic glomerular as well as mildly active glomerular lesions, and a chronic tubulointerstitial inflammatory infiltrate. (D) High-power view showing a
glomerulus with shrinkage of the capillary tuft and initial extra-capillary proliferation; tubular atrophy is also evident. (E) Low-power view showing hyaline changes in
medium-sized and small vessels, glomerulosclerosis, tubulointerstitial inflammation and diffuse interstitial fibrosis. (F) High-power view of a globally sclerosed glo-
merulus and chronic tubulointerstitial infiltrate. (A–D): periodic acid–Schiff staining, (E and F): Masson trichrome staining. Original magnification, 20 in (A), (C) and
(E), 40 in (B), (D) and (F). Scale bars are 150 lm in (A) (which also applies to C and E), and 75 lm in (B) (which also applies to D and F).
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classification, 6 biopsies (21%) were ‘focal’, 1 (4%) ‘crescentic’, 9
(32%) ‘mixed’ and 12 (43%) ‘sclerotic’ (Table 2).
Treatment and outcome
All patients received supportive therapy according to clinical
status. Seventeen (41%) were already taking angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers
before diagnosis. After diagnosis was made, 37 patients (90%)
were treated with immunosuppression. Twenty-three (56%) re-
ceived glucocorticoids alone (5/23) or combined with cyclophos-
phamide (14/23), mycophenolate mofetil (2/23) and azathioprine
(2/23), while 14 (34%) were administered a rituximab-based regi-
men. Two received rituximab alone because of contraindica-
tions to glucocorticoids (diabetes and atherosclerotic disease);
they had eGFR 15 mL/min/1.73 m2 and a ‘sclerotic’ pattern at
kidney biopsy. Moreover, four patients (10%) were not treated
with immunosuppression because they had no active extra-
renal disease and their renal recovery was considered unlikely.
The median (IQR) follow-up after diagnosis was 32 months
(12–52). Table 3 describes the renal outcome of the 34 patients
who received immunosuppression and did not require RRT at
treatment start. At Month 6, 32 (94%) had achieved renal re-
sponse and 25 (73%) reported eGFR improvement as compared
with diagnosis. Haematuria improved or subsided in all patients
while proteinuria showed initial decrease (Figure 3B).
At last follow-up, renal response was maintained among 23
patients (68%), of which 20 (59%) had eGFR improvement as
compared with diagnosis. Eleven (32%) had progressed and four
of them (12%) had started RRT; these patients had eGFR <15 mL/
min/1.73 m2 already at diagnosis and a ‘sclerotic’ pattern at kid-




















T0 T6 T12 T24


















T0 T6 T12 T24
33No. of patients 25 23 19
FIGURE 3: Evolution of eGFR and proteinuria after diagnosis. The plots show eGFR (A) and 24-h proteinuria (B) of patients with slowly progressive ANCA-associated re-
nal vasculitis at diagnosis (T0) and at Months 6 (T6), 12 (T12) and 24 (T24) after diagnosis. Patients who required RRT at T0 or did not receive immunosuppressive ther-
apy were excluded from the analysis. Data showed a significant increase in median eGFR and a significant decrease in median 24-h proteinuria over the first 24 months
after diagnosis (respectively, P¼0.0041 and P<0.001 using Friedman’s test). The boxes indicate the 25th–75th percentile, the bar inside the boxes indicates the median,
the whiskers indicate the 10th–90th percentile and the dots the outliers.
Table 3. Treatment and outcome of patients with slowly progressive ANCA-associated renal vasculitis at Months 6 and 12 after diagnosis
(baseline) and at last follow-up
n (%) Baseline Month 6 Month 12 Last follow-up
n¼ 41 n¼ 41 n¼ 33 n¼ 41
Type of treatment
No immunosuppressive therapy 4 (10) 4 (10) 4 (12) 4 (10)
Conventional immunosuppressive therapy 23 (56) 23 (56) 18 (55) 19 (46)
Rituximab-based therapy 14 (34) 14 (34) 11 (33) 18 (44)
ESRDa 15 (37) 10 (24) 5 (15) 12 (29)
RRT 6 (15) 7 (17) 4 (12) 10 (24)
Renal outcome in patients treated with immunosuppressionb n¼ 34 n¼ 28 n¼ 34
Response – 32 (94) 23 (82) 23 (68)
Improved GFR (25%)c – 25 (73) 19 (68) 20 (59)
Stable GFR (<25%) – 7 (21) 4 (14) 3 (9)
No response/progression – 2 (6) 5 (18) 11 (32)
RRT – 1 (3) 1 (4) 4 (12)
aESRD was defined as eGFR <15 mL/min/1.73 m2 established at two consecutive assessments or the need for RRT.
bPatients requiring RRT at the time of treatment start were excluded from the analysis.
cIn this subgroup of patients, the median (IQR) absolute eGFR increase was 14 mL/min (14–21) while the median (IQR) percent eGFR increase was 52% (34–65%).
Conventional immunosuppressive therapy included regimens based on glucocorticoids and immunosuppressive agents other than rituximab. Renal response was de-
fined as absence of vasculitis activity and documentation of improved or stabilized renal function as compared with baseline, with concomitant improvement of uri-
nary abnormalities.
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‘sclerotic’ had partial renal function improvement as compared
with diagnosis, with median (IQR) eGFR risen from 14 mL/min/
1.73 m2 (12–19) to 20 mL/min/1.73 m2 (18–27) (P¼ 0.05). The evo-
lution of eGFR through the first 24 months after diagnosis is
shown in Figure 3A.
The groups treated with rituximab-based and rituximab-free
immunosuppressive regimens reported similar rates of re-
sponse (Supplementary data, Table S2). Moreover, both patients
who received rituximab monotherapy had eGFR improvement
at Month 6 and at last follow-up (respectively, 9 and 45 months
after diagnosis). None of those who started RRT became RRT-
free. Moreover, all patients who did not receive immunosup-
pressive therapy progressed to or remained in ESRD.
Among patients with a follow-up of at least 12 months, 10/27
(37%) experienced a renal worsening with eGFR decline >25% af-
ter an initial response. Six also had worsening proteinuria and
haematuria. Moreover, ANCA were positive in all but their titre
was increased in only two as compared with previous assess-
ments. One patient had concomitant progression of pulmonary
fibrosis demonstrated by HRCT. No significant differences in
clinical and demographic features were observed between this
group and the remaining (data not shown). Five underwent re-
treatment or started a new therapy (rituximab) on the suspicion
of renal relapse, and four achieved again renal response.
Active extra-renal manifestations improved after treatment
in all patients. Interstitial lung lesions were found during
follow-up in four who had not previously undergone HRCT.
Moreover, one reported neurosensory hearing loss that signifi-
cantly improved with rituximab.
Nine patients (22%) died after a median (IQR) of 20 months (6–48).
None experienced a concomitant vasculitic flare or had treatment-
related adverse events that could have caused death. The identifi-
able causes of death were pulmonary embolism (1/9), hepatic insuf-
ficiency due to viral infection (1/9), intestinal perforation (1/9) and
pulmonary oedema due to heart failure (2/9).
DISCUSSION
Renal involvement in AAV includes a broad spectrum of mani-
festations that range from RPGN, the most common and severe
one, to less aggressive forms [5]. In this study, we characterized
a peculiar subset of AAV patients, hallmarked by slow progres-
sion of renal disease at presentation. Among a large multi-
centre cohort of GPA and MPA patients, we found that 5% had a
slow rather than rapid renal course, with gradual renal func-
tion deterioration and mild-to-moderate urinary abnormali-
ties. All were classified as MPA and most had advanced age,
positive MPO-ANCA and few or no vasculitic symptoms, while
the most frequent extra-renal manifestation was subclinical
interstitial lung disease. Renal histology showed predomi-
nance of chronic damage and scarce active lesions. However,
despite a poor renal prognostic profile, most patients treated
with immunosuppression had partial renal recovery at short-
and long-term follow-up.
To our knowledge, this is the first study that systematically
assesses slowly progressive renal AAV. The recognition of this
phenotype suggests that AAV occasionally presents with indo-
lent renal progression and scarce vasculitic features, particu-
larly among elderly patients. In such a clinical scenario, it may
be hard to suspect AAV. It also seems conceivable that a propor-
tion of patients with this AAV form has been overlooked, as
their renal disease was probably attributed to CKD of non-
specific aetiology, e.g. ‘nephrosclerosis’ or ‘hypertensive kidney
disease’ [18]. In order to identify these cases early, ANCA should
be tested soon after detection of CKD, especially among patients
with urinary abnormalities, progression despite nephroprotective
therapy and interstitial lung lesions. The ANCA status also helps to
decide on kidney biopsy and to evaluate its findings. Along with
diffuse chronic damage and some vascular changes compatible
with nephrosclerosis, i.e. arteriolar hyalinosis, our patients had
pauci-immune extracapillary proliferation, mainly at chronic
stages. We believe that these findings, although non-specific, are
consistent with renal AAV in ANCA-positive patients and suggest
that vasculitis contributes to renal damage in these forms, even if
more traditional factors could also play a role.
That immune-mediated mechanisms are involved in kidney
disease pathogenesis among these patients is further supported
by the renal function improvement observed in a substantial
proportion of cases following immunosuppressive therapy.
Notably, renal response was also achieved by those who re-
peated treatment for possible renal relapse. Kidney impairment
is usually considered irreversible in nephrosclerosis, where risk
factor control aims at preventing progression, while timely im-
munosuppression may lead to renal recovery in AAV. Whether
slowly progressive renal AAV should be treated with immuno-
suppression rather than with supportive care only is not an
easy question, since the long duration of renal disease with dif-
fuse sclerosis and few active lesions discourages treatment. Our
study could not provide evidence to solve this dilemma, but the
high frequency of renal response we reported is in favour of
immunosuppression.
The choice of management appears particularly intricate for
patients with severe renal function impairment and a ‘sclerotic’
pattern at kidney biopsy, i.e. the subgroup with the worst progno-
sis [19–21]. However, as shown in our cohort and in previous expe-
riences [22], some achieve renal stabilization with partial recovery,
thus neither for these cases should immunosuppression be a priori
excluded. It seems reasonable that these patients be treated with
light regimens and reduced glucocorticoid dose. With reagard to
this, we reported two cases that experienced sustained improve-
ment after rituximab monotherapy, which could represent a valid
therapeutic option for comorbid patients.
Although we screened a large number of GPA patients, gran-
ulomatous manifestations were never found among slowly pro-
gressive renal AAV cases, while MPO-ANCA strongly
characterized this group. These findings suggest a distinct path-
ogenic process underlying the slow renal course, likely orches-
trated by MPO-ANCA. These autoantibodies have been shown
to be nephritogenic, causing crescentic glomerulonephritis
when injected in murine models [23]. Moreover, MPO ANCA-
positive vasculitis is associated with more chronic damage at
kidney biopsy than PR3-ANCA-positive vasculitis [24, 25]. This
has been related to a possible diagnostic delay due to less extra-
renal involvement in MPO-ANCA-positive patients that would
allow active lesions to turn into chronic ones. Hauer et al. also
proposed that the process of renal sclerosis is enhanced in
MPO-ANCA-positive vasculitis and occurs already at early
stages [25]. Mechanisms that could explain this pattern have
not been explored; however, MPO-ANCA triggers lung fibrosis in
MPA and could have similar effects in the kidney [26, 27]. Slowly
progressive renal AAV could represent a disease subset in
which MPO-ANCA promote more renal sclerosis than vasculitis,
with consequent mild manifestations, slow progression and
chronic damage accrual. The reason why most MPO-ANCA-
positive patients develop RPGN and a small proportion has
slowly progressive renal disease is elusive; future studies are
needed to compare these two different subsets, e.g. by exploring
differences in genetic profiles and ANCA epitopes.
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Our study has limitations, mainly related to its retrospective
nature and the absence of established definitions to discrimi-
nate slowly progressive renal disease from more typical forms
of renal involvement, such as RPGN. However, the criteria we
chose to define slowly progressive renal AAV, although arbi-
trary, were quite stringent and in our opinion sufficient to dif-
ferentiate this presentation from other renal syndromes.
Further strengths of the study are the large size of the AAV co-
hort and the availability of long-term follow-up data.
In conclusion, AAV may present with slowly progressive
renal disease. This patient subset has MPA phenotype,
MPO-ANCA positivity, advanced age at diagnosis and subclini-
cal extra-renal involvement, mainly interstitial lung disease.
There is a danger of missed or delayed diagnosis for these cases,
with markedly increased ESRD risk, and ANCA test is crucial for
their recognition. Despite chronic renal injury, immunosuppres-
sive treatment may allow partial renal recovery and thus should
be considered in these forms.
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